Shanghai Pharmaceuticals Holding Co. Ltd.SSE: 601607

Announcement on Digoxin Tablets Passing Generic Drug Consistency Evaluation

Apr 9, 2026 · Issued by Shanghai Pharmaceuticals Holding Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 9, 2026

On 6ix: 6ix.com/news/announcement-on-digoxin-tablets-passing-generic-drug-consistency-evaluation

Announcement on Digoxin Tablets Passing Generic Drug Consistency Evaluation

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix

Earlier from Shanghai Pharmaceuticals

Announcement on Proposed Issuance of Debt Financing ProductsMar 31
Announcement on Convening the 2025 Annual Performance BriefingMar 27
Announcement on Completion of Generic Drug Consistency Evaluation for Cefazolin Sodium for InjectionMar 18
Announcement on Subsidiary Obtaining Philippine Drug Registration Certificate for Pregabalin CapsulesFeb 28
Announcement on Obtainment of Drug Registration Certificate for Rivaroxaban Tablets in SingaporeFeb 25

Later from Shanghai Pharmaceuticals

Announcement on Prednisolone Tablets Passing Generic Drug Consistency EvaluationApr 25
Announcement on Progress in Proposed Public Listing and Transfer of 30% Equity in Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd.Apr 29
Report for Q1 2026Apr 30
Announcement on Obtainment of Drug Registration Certificate for Rivaroxaban Tablets in ThailandMay 8
Announcement on the Interim Dividend Distribution Arrangement in 2026May 28

All Shanghai Pharmaceuticals news releases

Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.

Follow Shanghai Pharmaceuticals